Clinical trials
Aneurysm trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
24 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2008 | 1 |
| 2010 | 3 |
| 2012 | 1 |
| 2014 | 2 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 2 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 5 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 10 |
| Completed | 5 |
| Recruiting | 5 |
| Active, not recruiting | 2 |
| Not yet recruiting | 1 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| MicroPort NeuroTech Co., Ltd. | 3 |
| Hangzhou Endonom Medtech Co., Ltd. | 2 |
| Capital Medical University | 1 |
| Changhai Hospital | 1 |
| Chinese University of Hong Kong | 1 |
| Dongliang Zhang, MD | 1 |
| First Affiliated Hospital of Zhejiang University | 1 |
| Guangzhou University of Traditional Chinese Medicine | 1 |
| Lifetech Scientific (Shenzhen) Co., Ltd. | 1 |
| Lu Hua | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Aneurysm | 24 |
| Intracranial Aneurysm | 4 |
| Brain Diseases | 3 |
| Cardiovascular Diseases | 3 |
| Aortic Aneurysm | 2 |
| Aortic Aneurysm, Abdominal | 2 |
| Aortic Dissection | 2 |
| Subarachnoid Hemorrhage | 2 |
| Aortic Aneurysm, Thoracic | 1 |
| Aortic Aneurysm, Thoracoabdominal | 1 |
Trials
Showing 1 to 24 of 24. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.